{
  "nctrialId": "HC-1689",
  "title": "A  Double-Blind, Active-Controlled Multi-Center Study of DRM-581 (IL-17 inhibitor) in Patients With Crohn's Disease",
  "officialTitle": "A  Double-Blind, Active-Controlled Multi-Center Study of DRM-581 (IL-17 inhibitor) in Patients With Crohn's Disease",
  "sponsor": "Vancouver Coastal Health Research Institute",
  "indication": "Crohn's Disease",
  "phase": "Phase 1",
  "fileName": "HC-1689.json",
  "fileSize": 160356,
  "date": "2024-04-15",
  "completionDate": "2027-12-08",
  "drugName": "DRM-581 (IL-17 inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Terminated",
  "description": "This is a  double-blind, active-controlled multi-center study designed to evaluate the efficacy and safety of DRM-581 (IL-17 inhibitor) in patients with Crohn's Disease. The study will enroll approximately 148 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 21-63 years\n- Confirmed diagnosis of Crohn's Disease\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}